I have over 8 years experience in sales, finance, marketing, and real estate. Throughout my real estate career I have negotiated multi-million dollar development and management transactions. My areas of specialization include short sales, foreclosure properties, investment properties, and property management.
I know the intricacies of the whole Real Estate process from A to Z. This level of expertise allows me to offer high caliber service to every single one of my clients.
I have developed a strong network of Brentwood and Antioch Real Estate agents who regularly meet to discuss marketing strategies. Every week this exclusive network of Brentwood and Antioch Real Estate agents meet to exchange up and coming Real Estate listings. This type of networking goes beyond traditional agents by offering exclusive home buying opportunities. This group allows me to bring Brentwood and Antioch homes for sale to my clients before they hit the market.
I’m a resident of Antioch and have extensive marketing strategies to market your home
Looking forward to working with you!
Direct: (925) 628-1539
I have been a technology investor for over twenty-five years. My investing style includes a combination of Fundamental Analysis with Technical Analysis used for entry and exit points. I have followed several stocks involved in patent litigations including Rambus (RMBS), Interdigital (IDCC), Tessera (TSRA) and Star Scientific (STSI). I follow the actual trials, read the transcripts and the briefs and attempt to handicap the outcomes. I attend various hearings, trials, and oral arguments whenever possible, including appeals to the CAFC, and occasionally attend hearings/trials at various District Courts and the ITC. I have attended over 30 oral arguments at the CAFC and I have a good feel for the various judges.
Star Scientific (STSI) is my favorite stock for 2014. STSI has transformed themselves from a tobacco company to a Biopharma company in 2012 and 2013, and this year we will see the true value of the company now that scientific researchers are running the company. Star Scientific will also probably be changing their name in 2014, and may choose to become known as Rock Creek Pharmaceuticals (their division that produces Anatabloc). Although STSI has exited the tobacco manufacturing business (and settled with RJR for a paltry $5 Million), they still own key tobacco curing patents that have been validated by both the USPTO and the CAFC, and these patents don't expire until 2018. Star's new TSNA BDL patent (granted in 2012 by the USPTO) doesn't expire until 2030. I expect STSI (Rock Creek) to have a banner year in 2014 as the world starts to learn the miraculous ability of Anatabloc to treat a variety of auto immune diseases and other conditions associated with NF-kB inflammation (including MS, Rheumatoid Arthritis, Asthma, Crohn's, Parkinson's, Traumatic Brain Injury, Alzheimer's, and various types of cancer, etc). Rock Creek Pharmaceuticals should have more and more peer reviewed medical journal articles on the efficacy of Anatabloc coming out in 2014. I also expect that Rock Creek will file several drug applications (IND's) with the FDA in 2014. In addition, I expect Rock Creek Pharmaceuticals to team or partner with one or more Big Pharma companies for various human ailments as they pursue these IND's. For all these reasons, I expect Star Scientific to be at least a $10 stock before the end of the 2014, and possibly much higher than that.
Boaz Berkowitz has a unique interest being a Seeking Alpha contributor as he not only has a passion for writing and companies in general, but was also Seeking Alpha's Director of Contributor Relations from 2008 to 2011.
Boaz is currently the Founder & CEO of TalkMarkets, a first of its kind financial website. TalkMarkets is a smart site which covers the entire breadth of the diverse financial realm but is customized and tailored to each individual user. Your interests, preferences, and level of investment sophistication influence what content you see and in what medium. This ensures a browsing experience which is easy, quick and personally relevant. Additionally, we've made interacting easy by incorporating the best social media tools and creating a few of our own.
As the first ever contributor-owned website, TalkMarkets is truly unique and issues its founding contributors equity in the company.
Boaz has a diverse background, having begun his career at Bloomberg L.P. in Manhattan. Later he was lured into the world of e-commerce where for nearly six years he served as the Director of Online Operations for Saturn Enterprises. He has also consulted for several companies including Atlas Air Worldwide Holdings (AAWW), the world's largest operator of 747 cargo aircraft, and GLX, the first global online financial community specifically for investors.
Boaz's interests extend beyond writing - he is involved with several charitable and community organizations. He sits on the Board of Directors for Binghamton University's Hillel and has served as an auxiliary police officer for the NYPD at Manhattan's 24th precinct. Boaz has an unusually supportive and understanding wife and four amazing children.
Thomas Hawk is a digital media and technology enthusiast in the San Francisco Bay Area writing under a pen name.
Hawk is an investment advisor in a non technology related field and uses his pen name to separate his investment career and identity from his thoughts and opinions on new media and technology, both fields which neither he nor his firm advise or offer services for professionally.
Additionally, Thomas Hawk is the Chief Evangelist for the Photo Sharing Site Zooomr (http://zooomr.com/). Thomas Hawk's Digital Connection (http://thomashawk.com/) covers all things having to do with the new digital revolution -- including Microsoft, TiVo, Photography, Flickr, Digital Rights, and other topics regarding the power of personal technology.
Jeff Jarvis blogs about media and news at Buzzmachine.com (http://Buzzmachine.com). He is associate professor and director of the interactive journalism program at the City University of New York’s new Graduate School of Journalism (http://journalism.cuny.edu/). He is consulting editor of Daylife, a news startup. He writes a new media column for The Guardian. He consults for media companies. Until 2005, he was president and creative director of Advance.net, the online arm of Advance Publications. Prior to that, Jarvis was creator and founding editor of Entertainment Weekly; Sunday editor and associate publisher of the New York Daily News; TV critic for TV Guide and People; a columnist on the San Francisco Examiner; assistant city editor and reporter for the Chicago Tribune; reporter for Chicago Today. He says he is at work on a book.
I am the founder of asensio.com a noted short-selling organization recognized as the Pioneer of Activist Short Selling. It has successfully advocated against more than 52 companies that we believed to be misleading investors. Early on the New York Times called asensio.com's work "something radical and remarkable." I am a graduate of the University of Pennsylvania’s Wharton School and went to work in Venezuela during that nation’s economic boom period, which occurred after the Venezuelan government nationalized its domestic petroleum industry. I left Venezuela as government policy began to shift away from free markets to attend Harvard University’s Graduate School of Business where I obtained a Master’s degree in investment management and finance.
Read more about asensio.com's history here: http://www.asensio.com/?page_id=7 Read more about our work at asensio.com.
In 1996, asensio.com began releasing short-focused research on the internet, becoming the first organization of its kind, the innovator of Strong Sell recommendations, and was the first and remains the only SEC and FINRA registered broker-dealer to have focused on short-selling research and trading. Our status as a unique member of FINRA and a pioneer in activist short selling generated conflicts with other FINRA members and FINRA's staff determined to bar me from membership in their private organization. We are constantly attempting to correct this disagreement. Today the firm and the site are independent of FINRA.
A statement pertaining to the FINRA matter is available here http://www.asensio.com/?page_id=7370 A disclosure statement can be found at http://www.asensio.com/?page_id=7374
I have been investing in individual stocks for over 19 years. During that time, I have found that investing in what I know is more profitable than trying to understand something outside my area of expertise. I work in the field of commercial real estate finance, which has led to a greater understanding of capital intensive businesses such as real estate. I write financial articles because it forces me to be more disciplined about my own investing.
Andrew Left's Citron Research (http://www.citronresearch.com/) (formally known as Stocklemon.com) seeks to expose companies whose management is in some way misleading investors. Left digs into SEC filings, financials, management histories and other data to uncover such situations, and he is usually short the stocks he writes about. Mr. Left has been publishing for 7 years and has created a track record that is unrivaled in short selling. Mr. Left has been cited in Barron's, Wall St Journal, CNBC and other major publications repeatedly for his work. Mr. Left was also an invited speaker at the reknown Master Investor Conference.
Visit: Citron Research (http://www.citronresearch.com/)